Trump administration announces drug pricing deals with Teva, Astellas and others
The Trump administration announced new Medicaid drug pricing agreements with nine midsize biotechnology and pharmaceutical companies on Monday. These deals ensure drugs are provided at the lowest prices available anywhere. This expansion brings the total number of companies in the administration's most-favored-nation pricing program to 26. Trump claims this broader prescription drug pricing initiative will save Americans $600 billion. The move aims to ease overall drug costs by leveraging the most-favored-nation pricing model across a larger group of manufacturers.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The Trump administration announced drug pricing deals with nine pharmaceutical firms.
- ✓ The new agreements bring the total number of companies in the most-favored-nation pricing program to 26.
- ✓ The administration previously reached deals with 17 of the largest drugmakers, including Pfizer, Eli Lilly, and Amgen.
- ✓ The new deals involve midsize biotechnology and pharmaceutical companies regarding Medicaid pricing.
What changed
The administration added nine midsize firms to its most-favored-nation pricing program, increasing the total to 26 companies.
Live updates
-
Trump administration secures drug pricing deals with 9 pharmaceutical firms
The Trump administration announced new Medicaid drug pricing agreements with nine midsize biotechnology and pharmaceutical companies on Monday. These deals ensure drugs are provided at the lowest prices available anywhere. This expansion brings the total number of companies in the administration's most-favored-nation pricing program to 26. Trump claims this broader prescription drug pricing initiative will save Americans $600 billion. The move aims to ease overall drug costs by leveraging the most-favored-nation pricing model across a larger group of manufacturers.
Why it matters
The administration previously struck agreements with 17 of the world's largest drugmakers, including Amgen, Eli Lilly, and Pfizer. This strategy seeks to lower healthcare costs by requiring manufacturers to offer the government the best available price. Some experts question if the impact will be as extensive as the administration suggests.
What is confirmed
- The Trump administration announced drug pricing deals with nine pharmaceutical firms.
- The new agreements bring the total number of companies in the most-favored-nation pricing program to 26.
- The administration previously reached deals with 17 of the largest drugmakers, including Pfizer, Eli Lilly, and Amgen.
- The new deals involve midsize biotechnology and pharmaceutical companies regarding Medicaid pricing.
Still unconfirmed
- The prescription drug pricing initiative will save Americans $600 billion.
- Every drug under the new agreements will be at the lowest prices available anywhere.
What to watch next
- Expert analysis on the actual cost savings compared to administration claims
- Implementation timelines for the new Medicaid pricing agreements
confidence 90%Sources used for this update (9)
- CNBC — Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
- Reuters — Trump administration to announce drug pricing deals
- USA Today — Trump touts drug-pricing pacts with these 9 pharma manufacturers
- CBS News — Trump announces deal with 9 new pharmaceutical firms in move to ease drug costs
- baltimoresun.com — Trump: Prescription drug pricing initiative will save Americans $600 billion
- www.nbcnews.com — Trump announces new drug-pricing deals with 9 pharma companies
- www.yahoo.com — Trump announces Medicaid drug pricing deals with 9 firms
- time.com — What Trump's Most-Favored-Nation Deal Means for Drug Prices
- www.yahoo.com — Trump announces new drug pricing deals with 9 drugmakers
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community